World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
55648
World Ranking
15836
National Ranking
7968

Eleftherios P. Mamounas publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Eleftherios P. Mamounas sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 292 publications — 15th percentile

15% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Eleftherios P. Mamounas D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Eleftherios P. Mamounas sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Eleftherios P. Mamounas is affiliated with University of Florida Health in the United States and has a research focus primarily within medicine and biochemistry, genetics, and molecular biology. Their scholarly contributions span multiple subfields including cancer research, oncology, pulmonary and respiratory medicine, genetics, and radiology, nuclear medicine, and imaging.

The scientist's work centers notably on breast cancer, contributing extensively to studies involving breast cancer treatment and advanced therapies, HER2/EGFR pathways in cancer research, cancer treatment and pharmacology, BRCA gene mutations, estrogen and related hormone effects, and cancer genomics and diagnostics.

Frequent venues for publication include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Annals of Surgical Oncology
  • Clinical Breast Cancer

Significant recent papers by Eleftherios P. Mamounas include:

  • "Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials," published in 2021 in The Lancet Oncology
  • "Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study," published in 2021 in The Lancet Oncology
  • "Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations," published in 2020 in Annals of Surgical Oncology
  • "NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)," published in 2022 in Journal of Clinical Oncology
  • "Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14,324 women in 16 trials," published in 2023 in The Lancet

Collaborations are notable with frequent co-authors such as Norman Wolmark, Charles E. Geyer, Priya Rastogi, Reena S. Cecchini, and Hanna Bandos, reflecting a strong network in oncology and breast cancer research.

The body of work conducted by Eleftherios P. Mamounas encompasses a significant number of contributions in cancer treatment studies, reflecting a deep engagement with clinical and translational research that addresses therapeutic strategies, patient management, and outcomes in oncology. Their publications establish a substantive presence in top-tier journals, emphasizing ongoing contributions to evidence-based practices in cancer care.

Best Publications

  • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

    Edward H. Romond;Edith A. Perez;John Bryant;Vera J. Suman

  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta

  • Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

    B Fisher;J Bryant;N Wolmark;E Mamounas

  • Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

    B Fisher;A Brown;E Mamounas;S Wieand

  • Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial

    David N. Krag;Stewart J. Anderson;Thomas B. Julian;Ann M. Brown

  • Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    Gunter Von Minckwitz;Chiun Sheng Huang;Max S. Mano;Sibylle Loibl

  • Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

    Priya Rastogi;Stewart J. Anderson;Harry D. Bear;Charles E. Geyer

  • American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

    Eric P. Winer;Clifford Hudis;Harold J. Burstein;Antonio C. Wolff

  • Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial

    Bernard Fisher;James Dignam;Norman Wolmark;D Lawrence Wickerham

  • Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer : National surgical adjuvant breast and bowel project protocol B-27

    Harry D. Bear;Stewart Anderson;Roy E. Smith;Charles E. Geyer

  • Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: NSABP B-31

    Elizabeth Tan-Chiu;Greg Yothers;Edward Romond;Charles E. Geyer

  • Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

    Edith A. Perez;Edward H. Romond;Vera J. Suman;Jong Hyeon Jeong

  • The Benefit of Leucovorin-Modulated Fluorouracil as Postoperative Adjuvant Therapy for Primary Colon Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-03

    N Wolmark;H Rockette;B Fisher;D L Wickerham

  • Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

    Edith A. Perez;Edward H. Romond;Vera J. Suman;Jong Hyeon Jeong

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS

    Irene L. Wapnir;James J. Dignam;Bernard Fisher;Eleftherios P. Mamounas

  • Significance of ipsilateral breast tumour recurrence after lumpectomy.

    B Fisher;S Anderson;E.R Fisher;C Redmond

  • Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

    Eleftherios P. Mamounas;Gong Tang;Bernard Fisher;Soonmyung Paik

  • Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes' B Versus Dukes' C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, and C-04)

    Eleftherios Mamounas;Samuel Wieand;Norman Wolmark;Harry D. Bear

  • Bevacizumab added to neoadjuvant chemotherapy for breast cancer

    Harry D. Bear;Gong Tang;Priya Rastogi;Charles E. Geyer

Frequent Co-Authors

Norman Wolmark
Norman Wolmark University of Pittsburgh
Joseph P. Costantino
Joseph P. Costantino University of Pittsburgh
Sandra M. Swain
Sandra M. Swain Georgetown University Medical Center
Soonmyung Paik
Soonmyung Paik Yonsei University
Louis Fehrenbacher
Louis Fehrenbacher Kaiser Permanente
Bernard Fisher
Bernard Fisher University of Pittsburgh
Patricia A. Ganz
Patricia A. Ganz University of California, Los Angeles
Adam Brufsky
Adam Brufsky University of Pittsburgh
Charles E. Geyer
Charles E. Geyer University of Pittsburgh
Edwin R. Fisher
Edwin R. Fisher University of Pittsburgh

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always follow a single straight path. Today, there are various online degrees that complement or provide alternatives to traditional medical education in the USA.

For those interested in preventative care, an online degree nutrition program offers flexible learning to build expertise in dietetics and wellness—a vital area as patient care expands beyond hospitals.

If you’re passionate about management and leadership in healthcare, explore the best online mha programs. These are designed for professionals seeking to move into administrative roles within healthcare organizations.

Practicing nurses can now broaden their qualifications through rn bsn online programs no clinicals, which make achieving a BSN easier for those balancing work and study.

Advanced nursing careers are also supported by accredited dnp online programs. These streamline the process of earning a Doctor of Nursing Practice degree, opening leadership and specialist roles.

Whether you’re shifting focus or seeking advancement, these pathways demonstrate the diverse, flexible options available in modern medical education.

Best Scientists Citing Eleftherios P. Mamounas

Trending Scientists

Recently Published Articles